AU2020354634A1 - Oral pharmaceutical immediate release composition and method of treatment for weight loss - Google Patents

Oral pharmaceutical immediate release composition and method of treatment for weight loss Download PDF

Info

Publication number
AU2020354634A1
AU2020354634A1 AU2020354634A AU2020354634A AU2020354634A1 AU 2020354634 A1 AU2020354634 A1 AU 2020354634A1 AU 2020354634 A AU2020354634 A AU 2020354634A AU 2020354634 A AU2020354634 A AU 2020354634A AU 2020354634 A1 AU2020354634 A1 AU 2020354634A1
Authority
AU
Australia
Prior art keywords
denatonium
salt
oral
pharmaceutical
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020354634A
Other languages
English (en)
Inventor
Tien-Li Lee
Zhenhuan ZHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aardvark Therapeutics Inc
Original Assignee
Aardvark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aardvark Therapeutics Inc filed Critical Aardvark Therapeutics Inc
Publication of AU2020354634A1 publication Critical patent/AU2020354634A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2020354634A 2019-09-25 2020-09-24 Oral pharmaceutical immediate release composition and method of treatment for weight loss Pending AU2020354634A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905943P 2019-09-25 2019-09-25
US62/905,943 2019-09-25
PCT/US2020/052588 WO2021062061A1 (en) 2019-09-25 2020-09-24 Oral pharmaceutical immediate release composition and method of treatment for weight loss

Publications (1)

Publication Number Publication Date
AU2020354634A1 true AU2020354634A1 (en) 2022-04-14

Family

ID=75167128

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020354634A Pending AU2020354634A1 (en) 2019-09-25 2020-09-24 Oral pharmaceutical immediate release composition and method of treatment for weight loss

Country Status (8)

Country Link
US (1) US20220280457A1 (https=)
EP (1) EP4034082A4 (https=)
JP (1) JP7680762B2 (https=)
KR (1) KR20220106960A (https=)
CN (2) CN114786647B (https=)
AU (1) AU2020354634A1 (https=)
CA (1) CA3151431A1 (https=)
WO (1) WO2021062061A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3215858A1 (en) * 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound
WO2023064480A1 (en) 2021-10-14 2023-04-20 Aardvark Therapeutics Inc. Monohydrate salt of denatonium acetate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
KR20040063616A (ko) * 2003-01-08 2004-07-14 김원호 다이어트 식품용 조제
EP1991054A4 (en) * 2005-11-10 2012-04-25 Univ Minnesota SYSTEMIC PLANT STRENGTHENER
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
EP2582367A4 (en) * 2010-06-17 2013-11-27 California Inst Of Techn METHOD AND SYSTEM FOR MODULATING HORMONES AND RELATED METHODS, ACTIVE SUBSTANCES AND COMPOSITIONS
EP2661266B1 (en) * 2011-01-07 2020-09-16 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
EP3138900A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Detergent compositions and wrapping films therefor having at least two different aversive agents and methods related thereto
EP3138897A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Films at least 80 microns thick comprising aversive agents, unit dose detergent articles wrapped therein, uses and methods related thereto
EP3138898A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Water-soluble detergent articles wrapped in a film with an aversive agent mainly in the flanges or skirt thereof
US10835505B2 (en) 2018-06-11 2020-11-17 Aardvark Therapeutics, Inc. Oral pharmaceutical formulation for weight loss, diabetes and related disorders
US12201593B2 (en) 2018-07-02 2025-01-21 Aardvark Therapeutics Inc. Oral pharmaceutical formulations of bitter compounds for asthma
WO2020014494A1 (en) * 2018-07-11 2020-01-16 Aardvark Therapeutics Inc. Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension
EP4081201A4 (en) * 2019-12-24 2024-01-10 Aardvark Therapeutics Inc. Pharmaceutical composition for treatment or prevention of multiple inflammatory disorders

Also Published As

Publication number Publication date
CA3151431A1 (en) 2021-04-01
EP4034082A4 (en) 2023-07-05
WO2021062061A1 (en) 2021-04-01
JP2022549833A (ja) 2022-11-29
CN114786647B (zh) 2025-05-06
CN120420287A (zh) 2025-08-05
US20220280457A1 (en) 2022-09-08
EP4034082A1 (en) 2022-08-03
KR20220106960A (ko) 2022-08-01
CN114786647A (zh) 2022-07-22
JP7680762B2 (ja) 2025-05-21

Similar Documents

Publication Publication Date Title
AU2018241128B2 (en) Compositions and Methods for Transmucosal Absorption
US10835505B2 (en) Oral pharmaceutical formulation for weight loss, diabetes and related disorders
AU2002309429B2 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof
US8455667B2 (en) Duloxetine compositions in the form of a powder for suspension in a liquid
WO2022103639A1 (en) Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
WO2008122190A1 (en) The composition comprising l-carnitine or derivatives thereof and its use
US20220280457A1 (en) Oral pharmaceutical immediate release composition and method of treatment for weight loss
WO2022098879A1 (en) Sustained release solid dosage forms for modulating the colonic microbiome
CN102036669B (zh) 用于治疗早泄的药物组合物
US20150110865A1 (en) Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment
US20220087960A1 (en) Oral Pharmaceutical Immediate Release Composition
KR20160012706A (ko) 서방성 제제
CN101175477A (zh) 碘塞罗宁的控释药物组合物及其制备和使用方法
US20050089558A1 (en) Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
CN119679815B (zh) 一种治疗神经损伤引起的疼痛的组合物
US20070213324A1 (en) Stable pharmaceutical composition of carisoprodol and meloxicam
JPS59144717A (ja) 鎮痛剤
US20250152507A1 (en) Sublingual compositions for erectile dysfunction
CN115721636A (zh) 一种双多巴缓释组合物及其制备方法
RU2264814C2 (ru) Антигистаминная фармацевтическая композиция
CN111939139A (zh) 一种盐酸美金刚缓释和盐酸多奈哌齐速释胶囊及其制备方法
WO2008150191A1 (fr) Médicament anorexigène et permettant de réguler la masse corporelle
TW202010496A (zh) 双那布扶林己二酸酯和乙醯胺酚的藥物製劑及治療疼痛的方法
JP2019510057A (ja) 経口投与されるｇｈｂ又はその治療上許容可能な塩の一つの即時放出のための単位投薬量、および禁酒を維持するためのその使用
KR20060059022A (ko) 호박산 수마트립탄을 함유하는 약제학적 조성물